Twist Bioscience Inks Antibody Discovery Pact With MediSix Therapeutics

Twist Bioscience Corporation TWST and MediSix Therapeutics have collaborated to discover novel antibodies against five undisclosed targets.

  • Under the terms of the collaboration, Twist will leverage its proprietary Library of Libraries to discover five novel antibodies directed against MediSix's targets. 
  • MediSix will use its platform technologies to develop novel CAR T-cell therapies targeting malignancies and autoimmune diseases without any CAR T-cell fractricide. 
  • Twist will receive an upfront payment and will be eligible to receive success-based clinical and regulatory milestone payments and royalties on product sales.
  • Specific deal terms were not disclosed.
  • Related: Twist Bioscience Launches Synthetic RNA Positive Controls For SARS-CoV-2 Encapsulated Minicapsules.
  • "We look forward to collaborating with MediSix to overcome existing challenges of using cell therapy approaches to treat T-cell malignancies, often because of a lack of antigen targets specific to the cancer," said Emily M. Leproust, CEO and co-founder of Twist Bioscience. 
  • "In addition, with MediSix's locations in Boston, U.S. and Singapore, this agreement deepens our global footprint and presence in the Asia Pacific region, where certain types of T-cell cancers are more prevalent," Leproust added.
  • Price Action: TWST shares are down 3.28% at $47.22 during the market session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!